GlassScriptPhysician profile
Kaelyn E Cicco
NPI 1902115785
$3,415.64
in general payments reported to CMS, 2019-2025
28 companies · $484 in 2025
The $484 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $552 · 2022: $1,267 · 2023: $599 · 2024: $514 · 2025: $484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,596.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,596.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $438.17 | 2021-2025 | |
| Abbvie INC. | $374.71 | 2021-2025 | |
| Novo Nordisk INC | $338.05 | 2021-2025 | Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $333.01 | 2021-2025 | |
| Intuitive Surgical, INC. | $250.00 | 2022 | |
| Pfizer INC. | $237.27 | 2021-2025 | |
| Exeltis, USA INC. | $198.26 | 2021-2023 | Slynd |
| Biogen, INC. | $139.92 | 2025 | Zurzuvae |
| Organon LLC | $137.86 | 2021-2025 | Nexplanon |
| Astellas Pharma US INC | $131.40 | 2024-2025 | Veozah |
| Therapeuticsmd, INC. | $125.14 | 2022 | |
| Mylan Pharmaceuticals INC. | $101.32 | 2021-2022 | |
| Axonics, INC. | $79.13 | 2023-2024 | Bulkamid, Axonics |
| Aspira Women'S Health INC | $64.67 | 2023 | Ova1 |
| Exact Sciences Corporation | $62.22 | 2023-2024 | Cologuard Collection Kit |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $49.96 | 2021-2024 | Aptima |
| Evofem Biosciences, INC. | $43.15 | 2021 | |
| Roche Diagnostics Corporation | $42.97 | 2021 | |
| Agile Therapeutics, INC. | $39.74 | 2022 | |
| Merck Sharp & Dohme LLC | $39.29 | 2021-2023 | Gardasil 9 |
| Conmed Corporation | $37.05 | 2024 | Airseal |
| Millicent US INC | $35.60 | 2024-2025 | Femlyv, Intrarosa, Femring |
| Medtronic, INC. | $28.24 | 2022-2023 | Interstim |
| Olympus America INC. | $20.50 | 2024 | Pk Technology |
| Virtus Pharmaceuticals LLC | $19.61 | 2021 | |
| Sumitomo Pharma America, INC. | $17.69 | 2024 | Myfembree |
| Becton, Dickinson and Company | $16.96 | 2022 | |
| Avion Pharmaceuticals | $13.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaelyn Cicco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.